Alnylam Pharmaceuticals, Inc. (ALNY)
ALNYNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$151.68
-4.93 (-3.15%) today
Regular session, Nov 10, 2:44 PM ET
- Market cap
- $20.32bn
- P/E
- 7.9
- EPS, last 4 quarters
- $19.26
- Dividend yield
- –
- Day range
- $149.18 to $158.82
- 52-week range
- $152.17 to $479.79
- Average volume
- 1.98m
- Previous close
- $156.61
Analysts
25 coveringBuy18 buy, 7 hold, 0 sell
Targets a year out average $310.55, +104.7% from here
Earnings
next estimate $1.68Next report
Dec 2025
+9.3%
Mar 2026
+65.9%
Jun 2026
-16.0%
Sep 2026
+976.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $1.10bn | $1.17bn | $1.29bn | $1.46bn |
| Gross profit | $829.31m | $956.05m | $992.50m | $1.10bn |
| Operating income | $131.72m | $268.64m | $231.44m | $345.80m |
| Net income | $111.54m | $205.99m | $164.49m | $2.17bn |
Last four quarters: revenue $5.01bn, margin 52.9%, free cash flow $806.31m
News
8 latest- Alnylam's AMVUTTRA Shows Sustained Benefits Through Five Years In ATTR-CM RTTNews · 12 hours ago
- Alnylam Pharmaceuticals, Inc. Announces $1.0 Billion Share Repurchase Program and Departure of Chief Commercialization Officer Tolga TangulerFintel · 5 days ago
- 3 Nasdaq-100 Stocks That Can Double, According to Wall StreetThe Motley Fool · 6 days ago
- ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth ConcernsZacks · Oct 30, 2026
- Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial ResultsFintel · Oct 29, 2026
- Alnylam (ALNY) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 29, 2026
- Alnylam Pharmaceuticals Q3 Earnings Call HighlightsMarketBeat · Oct 29, 2026
- Alnylam Reports 17% Q3 Revenue Growth, Expands Nucresiran Trial And Advances RNAi Pipeline RTTNews · Oct 29, 2026
The company
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- alnylam.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.